Biomedical Engineering Reference
In-Depth Information
2007. Assessment of the biological and pharmacological ef ects of the alpha nu beta3
and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients
with advanced solid tumors. Ann. Oncol. 18(8): 1400-1407.
Hehlgans, S. and M. Haase, and N. Cordes. 2007. Signalling via integrins: implications for
cell survival and anticancer strategies. Biochim. Biophys. Acta 1775(1): 163-180.
Hiscox, S. and L. Morgan, T.P. Green, D. Barrow, J. Gee, and R.I. Nicholson. 2006. Elevated
Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer
cells. Breast Cancer Res. Treat. 97(3): 263-274.
Johnson, F.M. and B. Saigal, M. Talpaz, and N.J. Donato. 2005. Dasatinib (BMS-354825)
tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis
of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin.
Cancer Res. 11(19 Pt 1): 6924-6932.
Kallergi, G. and D. Mavroudis, V. Georgoulias, and C. Stournaras. 2007. Phosphorylation
of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast
cancer cells. Mol. Med. 13(1-2): 79-88.
Li, S. and Z.C. Hua. 2008. FAK expression regulation and therapeutic potential. Adv. Cancer
Res. 101: 45-61.
Luo, F.R. and Y.C. Barrett, Z. Yang, A. Camuso, K. McGlinchey, M.L. Wen, R. Smykla,
K. Fager, R. Wild, H. Palme, S. Galbraith, A. Blackwood-Chirchir, and F.Y. Lee. 2008.
Identii cation and validation of phospho-SRC, a novel and potential pharmacodynamic
biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer
Chemother. Pharmacol. 62(6): 1065-1074.
Matkowskyj, K.A. and K. Keller, S. Glover, L. Kornberg, R. Tran-Son-Tay, and R.V. Benya.
2003. Expression of GRP and its receptor in well-dif erentiated colon cancer cells
correlates with the presence of focal adhesion kinase phosphorylated at tyrosines 397
and 407. J Histochem. Cytochem. 51(8): 1041-1048.
Oliveira-Ferrer, L. and J. Hauschild, W. Fiedler, C. Bokemeyer, J. Nippgen, I. Celik, and G.
Schuch. 2008. Cilengitide induces cellular detachment and apoptosis in endothelial and
glioma cells mediated by inhibition of FAK/Src/AKT pathway. J. Exp. Clin. Cancer Res.
27(1):86.
Roberts, W.G. and E. Ung, P. Whalen, B. Cooper, C. Hulford, C. Autry, D. Richter, E.
Emerson, J. Lin, J. Kath, K. Coleman, L. Yao, L. Martinez-Alsina, M. Lorenzen, M.
Berliner, M. Luzzio, N. Patel, E. Schmitt, S. LaGreca, J. Jani, M. Wessel, E. Marr, M.
Grif or, and F. Vajdos. 2008. Antitumor activity and pharmacology of a selective focal
adhesion kinase inhibitor, PF-562,271. Cancer Res. 68(6): 1935-1944.
Ruest, P.J. and N.Y. Shin, T.R. Polte, X. Zhang, and S.K. Hanks. 2001. Mechanisms of CAS
substrate domain tyrosine phosphorylation by FAK and Src. Mol. Cell Biol. 21(22):
7641-7652.
Serrels, A. and I.R. Macpherson, T.R. Evans, F.Y. Lee, E.A. Clark, O.J. Sansom, G.H.
Ashton, M.C. Frame, and V.G. Brunton. 2006. Identii cation of potential biomarkers
for measuring inhibition of Src kinase activity in colon cancer cells following treatment
with dasatinib. Mol. Cancer h er. 5(12): 3014-3022.
Shi, Q. and A.B. Hjelmeland, S.T. Keir, L. Song, S. Wickman, D. Jackson, O. Ohmori, D.D.
Bigner, H.S. Friedman, and J.N. Rich. 2007. A novel low-molecular weight inhibitor of
focal adhesion kinase, TAE226, inhibits glioma growth. Mol. Carcinog. 46(6): 488-496.
